EUA of J&J COVID-19 vaccine possible in February, Warp Speed’s Slaoui says

The Janssen unit of Johnson & Johnson could complete the U.S. government-supported Phase III trial of its COVID-19 vaccine candidate by January, and if it is successful receive emergency use authorization from FDA in February, Moncef Slaoui, Operation Warp Speed’s chief scientific adviser, said Wednesday.

More than 28,000 participants have been enrolled in the global 60,000-person trial, Slaoui said. He emphasized the potential benefit of the single dose regimen. ...